These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 23866347)

  • 1. Eplerenone and chronic heart failure. No comparison with spironolactone.
    Prescrire Int; 2013 Jun; 22(139):148-9. PubMed ID: 23866347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
    Rossignol P; Dobre D; McMurray JJ; Swedberg K; Krum H; van Veldhuisen DJ; Shi H; Messig M; Vincent J; Girerd N; Bakris G; Pitt B; Zannad F
    Circ Heart Fail; 2014 Jan; 7(1):51-8. PubMed ID: 24297687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldosterone antagonists in heart failure.
    Guglin M; Kristof-Kuteyeva O; Novotorova I; Pratap P
    J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):150-9. PubMed ID: 21160084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Eplerenone for treatment of heart failure].
    Yoshimura M
    Nihon Rinsho; 2007 May; 65 Suppl 5():153-8. PubMed ID: 17569313
    [No Abstract]   [Full Text] [Related]  

  • 6. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risks and benefits of aldosterone antagonists.
    Sica DA
    Curr Heart Fail Rep; 2005 Aug; 2(2):65-71. PubMed ID: 16036053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eplerenone reduces morbidity and mortality after acute MI.
    Cardiovasc J S Afr; 2006; 17(5):280. PubMed ID: 17117244
    [No Abstract]   [Full Text] [Related]  

  • 9. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
    Pitt B; Bakris G; Ruilope LM; DiCarlo L; Mukherjee R;
    Circulation; 2008 Oct; 118(16):1643-50. PubMed ID: 18824643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial.
    Walsh M; Manns B; Garg AX; Bueti J; Rabbat C; Smyth A; Tyrwhitt J; Bosch J; Gao P; Devereaux PJ; Wald R
    Clin J Am Soc Nephrol; 2015 Sep; 10(9):1602-8. PubMed ID: 26138259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: eplerenone: an underused medication?
    Abuannadi M; O'Keefe JH
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):318-25. PubMed ID: 20876342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
    Vardeny O; Claggett B; Anand I; Rossignol P; Desai AS; Zannad F; Pitt B; Solomon SD;
    Circ Heart Fail; 2014 Jul; 7(4):573-9. PubMed ID: 24812304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New therapy update. Inspra (eplerenone tablets).
    Kloner RA
    Congest Heart Fail; 2003; 9(6):341-2. PubMed ID: 14688507
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
    Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C
    Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ; Howard PA
    Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The EMPHASIS-HF study].
    Boccanelli A; Agostoni P
    G Ital Cardiol (Rome); 2011 May; 12(5):315-8. PubMed ID: 21593949
    [No Abstract]   [Full Text] [Related]  

  • 18. Hyperkalaemia in the age of aldosterone antagonism.
    Chapagain A; Ashman N
    QJM; 2012 Nov; 105(11):1049-57. PubMed ID: 22723454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eplerenone in chronic heart failure with depressed systolic function.
    Volterrani M; Iellamo F
    Int J Cardiol; 2015 Dec; 200():12-4. PubMed ID: 26044084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spironolactone therapy in heart failure patients with chronic kidney disease.
    Lopes R; Lourenco P; Mascarenhas J; Azevedo A; Bettencourt P
    Clin Cardiol; 2009 Oct; 32(10):597. PubMed ID: 19911355
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.